GHK-Cu50mg
As, Cd, Pb, Hg: not detected
Screens the vial for arsenic, cadmium, lead and mercury.
Batch GHKC-CA-26I-100 · 100mg vial
View heavy metals report →Endotoxin and heavy-metals testing is done periodically on selected batches to verify quality — not on every batch. Each result applies to the batch shown.
GHK-Cu Canada — 50 mg, 100 mg Lyophilized Vials
Copper Peptide Research Compound
GHK-Cu is a copper-binding peptide widely examined for its role in cellular repair signaling and tissue remodeling processes in laboratory studies. Research often focuses on its influence on collagen-related activity, skin-associated pathways, and overall regenerative mechanisms within controlled experimental settings.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
GHK-Cu is a synthetic copper-binding tripeptide composed of glycine, histidine, and lysine complexed with copper ions. It is developed for controlled laboratory research involving peptide–metal interaction systems.
In scientific literature, GHK-Cu is studied in experimental models examining extracellular matrix signaling pathways, cellular communication frameworks, and tissue-related regulatory mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
GHK-Cu was first identified in the 1970s as a naturally occurring copper-binding peptide. Research has examined its interaction with extracellular matrix components, metalloproteinase signaling systems, and cellular regulatory pathways within controlled laboratory environments.
Experimental studies evaluate peptide–metal complex dynamics and pathway-level signaling frameworks under in vitro and preclinical research conditions.
The tripeptide GHK was originally isolated from human plasma and later identified as a copper-binding complex. Early investigations explored its biochemical properties and signaling interactions, leading to expanded research into extracellular matrix regulation and peptide-mediated cellular communication.
Over time, GHK-Cu became a widely studied peptide–metal complex within structural and signaling research models.
Laboratory investigations into GHK-Cu have focused on extracellular matrix interaction models, metalloproteinase-related pathways, and peptide–metal complex signaling systems. Research frameworks evaluate copper-binding dynamics and cellular regulatory mechanisms under controlled in vitro and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on extracellular or matrix. This heading marks where GHK-Cu is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on metalloproteinase. This heading marks where GHK-Cu is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Maquart 1988, Maquart 1993, Pickart 2015. The work appeared in J Clin Invest. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Pickart 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published between 1988 and 2015 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for GHK-Cu, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
GHK-Cu is also referred to as copper peptide, GHK, blue copper.
Described as a collagen-stimulating and skin-regenerating peptide.
GHK-Cu is a copper-binding tripeptide first isolated from human plasma, and the published research examines its role in collagen synthesis, matrix remodelling and wound-healing models — largely in cell culture and animal studies, with some work on topical cosmetic formulations. Loren Pickart, who first characterised it, is the author of much of the foundational work. Results from topical cosmetic studies do not transfer to other contexts.
Described as broadly beneficial across skin, hair, lung and neurological conditions.
The breadth of that claim comes largely from gene-expression studies reporting that GHK modulates the expression of a very large number of human genes. Broad transcriptional effects in cell culture are a hypothesis-generating finding, not evidence of clinical benefit in any one of those areas, and the individual indications have not been tested in controlled human trials.
Described as safe because copper is an essential trace element.
Copper being essential in trace amounts says nothing about the safety of a copper-carrying peptide delivered in a research context. Copper homeostasis is tightly regulated and copper overload is itself a recognised toxicity. No human clinical safety data has been published for GHK-Cu outside topical cosmetic use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for GHK-Cu is per lot, not per product. Across the strengths currently stocked: 50mg lot GHK-CA-26A-02 returned 99.835% purity, 61.87 mg measured, 123.7% of the labelled 50 mg; 100mg lot GHKC-CA-26I-100 returned 99.779% purity, 112.46 mg measured, 112.5% of the labelled 100 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is GHK-Cu; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for GHK-Cu, across the strengths stocked they run from 112.5% to 123.7% of label. Both numbers are published for every lot, whichever way they fall.
Each strength of GHK-Cu carries its own lot code and its own certificate — GHK-CA-26A-02, GHKC-CA-26I-100 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy GHK-Cu in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
GHK-Cu is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 3 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 120mg of lyophilized GHK-Cu. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.
PubMedIn vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest 92(5):2368–2376.
PubMedGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$144.95CAD
